Degradation of viral DNA in cell nucleus opening up new treatment for hepatitis B — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/02/140221103926.htm
source : http://www.sciencedaily.com/releases/2014/02/140221103926.htm
source : http://www.sciencedaily.com/releases/2014/02/140219160416.htm
source : http://www.sciencedaily.com/releases/2014/01/140127141902.htm
In December, the research team of Antonio Giordano, a pathologist, Director and Founder of the Sbarro Health Research Organization in Philadelphia, PA, and Professor of Pathology and Oncology at the University of Siena, Italy, published two separate studies aiming to address the urgent need to identify possible new methods for mesothelioma treatment. In the first study, published in the scientific journal Cell Cycle, Giordano’s researchers tested on mesothelioma cells the effect of two drugs designed to reactivate the p53 protein, one of the most important ‘tumor suppressors’, which is turned off in most human cancers. "In mesothelioma, although p53 is rarely mutated, it is inactivated by alterations in its pathway," says Francesca Pentimalli of the National Cancer Institute of Naples, Italy, lead author of the study. …
The investigators constructed a live recombinant bacterial vaccine, expressing the H. pylori antigen, adhesin Hp0410, in the food-grade bacterium, Lactobacillus acidophilus…
Dr. Andrew Bottomley, EORTC Headquarters Associate Director says, "This study utilized a single standardized and validated patient self-assessment tool, the EORTC Core Quality of Life Questionnaire, or the QLQ-C30 for short. We selected thirty EORTC randomized controlled trials which involved eleven different cancer sites for this study. …
No effective preventative strategy is currently available for canker sore, but prospective trials of low-level laser therapy (LLLT) done in HNSCC patients undergoing chemoradiotherapy showed promising results. However, additional trials detected a high incidence of canker sore among patients, leaving the question of whether LLLT can effectively prevent canker sore still open. Now, a group of scientists led by Dr. Heliton Spindola Antunes at the National Cancer Institute (INCA) in Rio de Janeiro, Brazil, has successfully performed a definitive trial showing that LLLT reduces the occurrence of canker sore in HNSCC patients undergoing concurrent chemoradiotherapy and improves patient’s quality of life…
"This is the first mutation found that can explain the gender disparity in incidence of hepatocellular carcinoma," says Bum-Joon Kim of Seoul National University, Korea, an author on the study. In the study, the researchers randomly collected and analyzed serum samples from 292 patients with chronic HBV infection who visited one of 3 hospitals in Korea from 2003-2005. Previous studies had suggested that a gene mutation known as W4P/R was associated with higher incidence of liver cancer and cirrhosis. They developed an assay to specifically identify HBV with the W4P/R mutation…
Writing in the October 7 Early Edition of PNAS, Lars Eckmann, MD, professor of medicine, and colleagues describe creating more than 650 new compounds by slightly altering structural elements of metronidazole and other 5-nitromidazoles (5-NI), a half-century-old class of antimicrobial drugs used to combat everything from an ulcer-causing stomach bacterium to a gut-churning protozoan found in contaminated water. "The basic building blocks of 5-NI drugs are the same for all. We decorated around them, adding extra molecular pieces to change their shapes and sizes," said Eckmann, who published the paper with colleagues at UC San Diego, The Scripps Research Institute and the Queensland Institute of Medical Research in Australia…
The six "microRNA" molecules were already known to be overproduced in lymphomas and in many other human cancers, but no one had demonstrated that they can be the prime cause of such cancers — until now. The new study also identified the major biological pathways through which these microRNAs ignite and maintain cancerous growth. "We were able to show how this microRNA cluster can be the main driver of cancer, and so we now can start to think about therapies to combat its effects," said TSRI Assistant Professor Changchun Xiao. Xiao was the senior investigator for the study, which appeared this week in an advance online version of the EMBO Journal, a publication of the European Molecular Biology Organization. …